Cost-effectiveness of artesunate for the treatment of severe malaria.

Lubell, Y; Yeung, S; Dondorp, AM; Day, NP; Nosten, F; Tjitra, E; Abul Faiz, M; Bin Yunus, E; Anstey, NM; Mishra, SK; Mohanty, S; White, NJ; Mills, AJ; (2009) Cost-effectiveness of artesunate for the treatment of severe malaria. Tropical medicine & international health, 14 (3). pp. 332-7. ISSN 1360-2276 DOI:

Full text not available from this repository. (Request a copy)


OBJECTIVE: To explore the cost-effectiveness of artesunate against quinine based principally on the findings of a large multi-centre trial carried out in Southeast Asia. METHODS: Trial data were used to compare mortality of patients with severe malaria, treated with either artesunate or quinine. This was combined with retrospectively collected cost data to estimate the incremental cost per death averted with the use of artesunate instead of quinine. RESULTS: The incremental cost per death averted using artesunate was approximately 140 USD. Artesunate maintained this high level of cost-effectiveness also when allowing for the uncertainty surrounding the cost and effectiveness assessments. CONCLUSION: This analysis confirms the vast superiority of artesunate for treatment of severe malaria from an economic as well as a clinical perspective.

Item Type: Article
Faculty and Department: Academic Services & Administration > Academic Administration
Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Faculty of Public Health and Policy > Dept of Global Health and Development
Research Centre: Malaria Centre
PubMed ID: 19187518
Web of Science ID: 263467200010


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item